PTCL study finished on June 30 - Genfleet (running the China 009) buying back its own shares
Interesting timing...
GenFleet just announced a HK$350 million share buyback, stating it believes its shares are undervalued:
https://www.minichart.com.sg/2026/06/29/genfleet-therapeutics-announces-hk350-million-h-share-repurchase-to-enhance-shareholder-value-2026/
Why does that matter to SELLAS investors?
GenFleet is the company that discovered and is developing SLS009 (GFH009), which it licensed to SELLAS.
Also, according to ClinicalTrials.gov, the Phase Ib/II PTCL study of SLS009 reached its listed study completion date on June 30, 2026:
https://clinicaltrials.gov/study/NCT05934513
A few reminders:
- Early PTCL data showed 4 responses in 11 evaluable patients (36.4% ORR).
- PTCL is a rare, aggressive T-cell lymphoma with limited treatment options.
- Positive updated PTCL data would provide additional validation of SLS009 beyond AML.
REGAL remains the primary near-term catalyst for SELLAS, but encouraging PTCL data would strengthen the broader SLS009 story and could expand its commercial potential.
Interesting few weeks ahead.